Loading ...
Sorry, an error occurred while loading the content.
 

PR: Entremed's Endostatin

Expand Messages
  • BEN HAINES
    Greetings, Latest press release regarding Endostatin: Please note: With the crystal structure of Endostatin(TM) completely defined, we can now characterize
    Message 1 of 1 , Jun 1, 1998
      Greetings,
      Latest press release regarding Endostatin:

      Please note:
      "With the crystal structure of Endostatin(TM) completely defined, we can
      now characterize specific mechanisms in detail, enabling the design of
      molecular cousins with the potential for greater biological activity,'' stated Dr.
      John W. Holaday, EntreMed Chairman, President and Chief Executive
      Officer.

      -Ben(KIA)

      ---8<---8<----


      Monday June 1, 11:01 am Eastern Time

      Company Press Release

      Crystal Structure of EntreMed Inc.'s Endostatin-TM Protein Revealed

      Company Signs Sponsored Research Agreement with Leading Harvard
      Scientist

      ROCKVILLE, Md.--(BW HealthWire)--June 1, 1998--EntreMed Inc.
      (NASDAQ:ENMD - news) Monday announced that the crystal structure of its
      leading cancer-fighting product candidate, Endostatin(TM) protein, has been
      revealed by Dr. Bjorn R. Olsen, of Harvard Medical School, and a team of
      crystallographers from London and Germany.

      Dr. Olsen's article, ``Crystal Structure of the Angiogenesis Inhibitor
      Endostatin at 1.5A Resolution,'' was recently published in EMBO (Vol. 17,
      1998), the Journal of the European Molecular Biology Organization.

      Endostatin(TM) protein, discovered by Drs. Judah Folkman and Michael
      O'Reilly at Children's Hospital in Boston in 1996, is a potent antiangiogenic
      agent that shrinks cancerous tumors in mice by blocking new blood vessel
      formation. As reported in Nature (Vol. 390, 1997) drug resistance did not
      occur when Endostatin(TM) protein was repeatedly administered to
      mice.

      The genetically engineered version of Endostatin(TM) protein caused nearly
      complete suppression of tumor-induced angiogenesis and tumor growth in
      both mouse cancers and human cancers, when grown in mice. ``These
      observations raise the possibility that Endostatin(TM), or related peptides,
      may be of clinical use as effective antitumor agents,'' stated Dr.
      Olsen.

      Further advancing the science relating to its leading product candidate,
      EntreMed signed a sponsored research agreement with Harvard Medical
      School to fund Dr. Olsen's research until 2001. Complementing the work of
      EntreMed's key collaborator, Dr. Folkman, Dr. Olsen and his colleagues will
      continue to examine the mechanisms that allow Endostatin(TM)
      to inhibit the growth of endothelial cells necessary for the formation of new
      blood vessels.

      ``With the crystal structure of Endostatin(TM) completely defined, we can
      now characterize specific mechanisms in detail, enabling the design of
      molecular cousins with the potential for greater biological activity,'' stated Dr.
      John W. Holaday, EntreMed Chairman, President and Chief Executive
      Officer. Holaday continued, ``Adding Dr. Olsen's research efforts to
      our collaboration with Dr. Folkman and his team at Children's Hospital
      significantly reinforces our capabilities to expedite the development of
      Endostatin(TM) for clinical and commercial applications.''

      Endostatin(TM) protein is efficiently produced by yeast that were genetically
      engineered by EntreMed scientists. The Endostatin(TM)-generating yeast is
      now being grown in pilot-scale fermenters in preparation for preclinical and
      Good Manufacturing Practice (GMP) production for human clinical trials.
      EntreMed continues to work closely with the National Cancer Institute to
      advance development of Endostatin(TM) as well as other antiangiogenic
      product candidates, 2-methoxyestradiol, and thalidomide. Bristol-Myers
      Squibb Company [NYSE:BMY - news] is EntreMed's strategic partner for
      clinical development of Angiostatin(TM) protein.

      Rockville-based EntreMed, an innovative biopharmaceutical company, is a
      leader in the field of antiangiogenesis research, which involves the inhibition
      of abnormal blood vessel growth believed to be associated with a broad
      range of diseases. The Company's strategy is to accelerate development of
      its current core technologies through collaborations and sponsored
      research programs with university medical departments, research companies
      and government laboratories. In December 1995, EntreMed forged a
      strategic partnership with Bristol-Myers Squibb Company to further the
      preclinical and clinical development of Angiostatin(TM) protein and
      thalidomide analogs.

      For further information, please visit the EntreMed Web site at
      www.entremed.com.

      Statements herein that are not descriptions of historical facts are
      forward-looking and subject to risk and uncertainties. Actual results could
      differ materially from those currently anticipated due to a number of factors,
      including those set forth in the Company's Securities and Exchange
      Commission filings under ``Risk Factors,'' including risks relating to the early
      stage of products under development; uncertainties relating to clinical trials;
      dependence on third parties; future capital needs; and
      risks relating to the commercialization, if any, of the Company's proposed
      products (such as marketing, safety, regulatory, patent, product liability,
      supply, competition and other risks).

      Contact:

      EntreMed Inc., Rockville
      Mary P. Sundeen
      Director of Research Operations/Communications
      301/738-2490
      or
      Susan J. Lewis, 303/804-0494
    Your message has been successfully submitted and would be delivered to recipients shortly.